Cigna's response to COVID-19

https://static.cigna.com/assets/chcp/resourceLibrary/medicalResourcesList/medicalDoingBusinessWith Cigna/medicalDbwcCOVID-19.html

Cigna Coronavirus (COVID-19) Interim Billing Guidance for Providers for Commercial Customers

Updated April 9, 2020 Highlighted text indicates updates

As the COVID-19 pandemic continues to spread throughout the United States, we appreciate that providers across the country are on the front line to offer dedicated care to our customers and help protect local communities.

We also know it's more important than ever for Cigna to be committed to our customers' health and make it as easy as possible for you to focus on delivering safe, efficient, and quality care.

To honor this commitment, Cigna recently announced that we will:

- Waive customer cost-sharing related to COVID-19 screening, testing and treatment through May 31, 2020
 - The treatments that Cigna will cover for COVID-19 are those covered under Medicare or other applicable state regulations. We will reimburse health care providers at Cigna's innetwork rates or Medicare rates, as applicable. This policy applies to customers in the United States who are covered under Cigna's employer/union sponsored insured group health plans, insured plans for US based globally mobile individuals, Medicare Advantage and Individual and Family Plans (IFP). Cigna will also administer the waiver to self-insured group health plans and the company encourages widespread participation, although these plans will have an opportunity to opt-out of the waiver option.
- Waive customer cost-sharing for telehealth screenings for COVID-19 through May 31, 2020
- Make it easier for customers to be treated virtually for routine medical examinations by providers
- Provide free home delivery of up to 90-day supplies for Rx maintenance medications available through the Express Scripts Pharmacy and 24/7 access to pharmacists
- Make it easier for hospitals to transfer patients to long term acute care hospitals (LTACHs), skilled nursing facilities (SNFs), and acute rehabilitation facilities (AR) to help manage the demands of increasingly high volumes of COVID-19 patients
- Support Cigna doctors and nurse practitioners who wish to support their medical communities
- Support customers with a free, interactive, COVID-19 risk assessment tool

To further this commitment, we are providing this COVID-19 billing and reimbursement guidance to help ensure you can keep delivering the care you need to – in the office, at a facility, or virtually – all while getting properly reimbursed for the services you provide our customers.

Please note that we continue to proactively gather answers to key questions you may have, and will update information on this page as it is available.

Expand/Collapse All FAQs

Interim Billing Guidelines for Coronavirus (COVID-19)

| <u>Service</u> | Code(s) to bill | <u>Comments</u> |
|--|---|---|
| Virtual screening telephone consult (5-10 minutes) | G2012 | Effective through at least May 31, 2020 Must be performed by a licensed provider Cost-share will be waived |
| Virtual or face-to-face visit for screening for suspected or likely COVID-19 exposure | Usual face-to-face E/M code ICD10 code Z03.818 or Z20.828 Modifier CR on CMS1500 claims Condition code DR on UB04 claims Append with GQ, GT or 95 modifier for virtual care | Effective through at least May 31, 2020 Cost-share will be waived |
| Virtual or face-to-face visit for treatment of a confirmed COVID-19 case | Usual face-to-face E/M code ICD10 code B97.29 or U07.1 Append with GQ, GT or 95 modifier for virtual care | Cost-share will be waived Cigna will reimburse usual face- to-face rates Effective for dates of service on and after February 4, 2020 |
| COVID-19 laboratory testing | U0001, U0002, and 87635 | Laboratory test must be FDA- approved/authorized Reimbursement at 100% of Medicare Cost-share will be waived |
| Diagnostic COVID-19 related laboratory tests (other than COVID-19 test) | Usual codes | For other laboratory tests when COVID-19 may be suspected Cost-share will be waived |

ROSEN, SAPPERSTEIN & FRIEDLANDER, LLC

| | ICD10 code Z03 or Z20.828 Modifier CR on CMS1500 claim Condition code UB04 claims | 15 |
|--|--|--|
| <u>Service</u> | <u>Code(s) to bill</u> | <u>Comments</u> |
| Virtual screening telephone consult (5-10 minutes) | G2012 | Effective through at least May 31, 2020 Must be performed by a licensed provider Cost-share will be waived for all services (including non COVID-19 related services) |
| Non COVID-19 virtual visit (i.e., telehealth) | Usual face-to-face E/M code Append with GQ, GT or 95 modifier POS service normally billed See important notes below | Exception during public health emergency Effective through at least May 31, 2020 Cigna will reimburse usual face-to-face rates Services can be performed by phone, video, or both Standard cost-share will apply |
| Non-COVID-19 laboratory tests | Usual laboratory codes | Paid per contract If coded with Z codes, cost-share will be waived |
| In-office visit not related to COVID-19 | Usual face-to-face E/M codes | Normal cost-share will apply |

Provider Frequently Asked Questions for Coronavirus (COVID-19)

ROSEN, SAPPERSTEIN & FRIEDLANDER, LLC

405 York Road, Towson, MD 21204 • Phone: 410.581.0800 • Fax: 410.581.2268 • Email: info@rsandf.com • www.rsandf.com

BALTIMORE • ANNAPOLIS • COLUMBIA • DELRAY BEACH (FL)